.png?width=700&name=New-ATE-Logo2019%20(1).png)
Next-Generation At-Line Cell
Culture Media Analysis Enables
Real-Time Data-Driven Optimization
Presenters:
Ashley BellAshley has held scientific roles across leading research institutions and biopharmaceutical companies, including The Institute for Systems Biology, Amgen, and Bristol-Myers Squibb. Her work has focused on applying high-resolution analytical techniques to solve complex challenges in proteomics, product characterization, and process development. She has contributed to the development and optimization of biologics pipelines at multiple stages, from early discovery to late-phase development.
In her current role, Ashley works closely with key biopharma accounts and leads a global team of field application scientists. Her team supports the implementation of real-time, at-line analytical technologies to advance upstream process understanding, optimize cell culture conditions, and accelerate decision-making. Her scientific credibility and ability to connect bench-level science with business impact make her a strong advocate for broader PAT adoption.
Ashley earned her bachelor's degree in chemistry from California State University, Bakersfield. She has received multiple recognitions throughout her career, including the Doris A. Howell Foundation Award for Women’s Health Research and several innovation awards at Amgen for her contributions to product pipeline advancement. She is a contributing author on peer-reviewed publications and is known across the industry for her collaborative, science-first approach to technical leadership
Scott Miller, PhDScott was a co-founder of 908 Devices, where he helped pioneer miniaturized mass spectrometry systems and led application development and engineering teams that brought powerful analytical platforms into both field and bioprocessing environments. He played a critical role in launching solutions that have redefined speed and simplicity in real-time bioprocess analysis.
Prior to 908 Devices, Scott held senior technical roles at Ahura Scientific and Thermo Fisher Scientific, where he led several high-profile, government-funded R&D programs focused on portable chemical and biological detection. He also served as principal scientist at BioProcessors Corporation, developing automated microscale cell culture systems that laid the groundwork for early bioprocess intensification strategies.
Scott earned his doctoral degree in physical chemistry from Northwestern University and completed his postdoctoral research at MIT, where he further honed his interdisciplinary approach to innovation. He is the author of numerous peer-reviewed publications and holds multiple patents in analytical instrumentation and bioprocessing technologies.
At Repligen, Scott continues to bridge cutting-edge science with practical engineering to advance PAT adoption and deliver smart, user-centered solutions that empower biopharmaceutical manufacturers to optimize performance, ensure quality, and accelerate development.
Jérémie BarbauJérémie Barbau works as a senior application scientist at Repligen. He is a customer-facing expert with proficiency in bioprocessing who bridges the gap between product development and market adoption, ensuring customer success through deep technical knowledge and hands-on implementation.
Before joining Repligen, he held a position of bioprocessing expert, field applications at 908devices. For the last 20 years, he has worked at various positions/levels in the biopharmaceutical process development world, for companies ranging from well established pharmaceutical companies to smaller, startup-like structures, giving him a broad overview of the challenges and solutions specific to the biopharmaceutical industry.
